{"podcast":{"title":"EP Edge Journal Watch: Cardiac Electrophysiology Research","slug":"ep-edge-journal-watch-7561379","podcast_index_feed_id":7561379,"rss_url":"https://feeds.transistor.fm/ep-edge-journal-watch","website_url":null,"image_url":"https://img.transistorcdn.com/KWuXQ6fPAArQRCgfrqrxfzQNWh_DnAU4t75wkubUSk4/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9jMzFi/ZTYxOTI1M2U4NGRj/OGZmZjBhMDFlMjFm/NDQwMC5wbmc.jpg","author":"Niraj Sharma","episode_count":45,"summary":"Welcome to EP Edge Journal Watch, where cardiac electrophysiology meets evidence, precision, and perspective. Hosted by Dr. Niraj Sharma, this weekly podcast distills high-impact cardiovascular and Cardiac Electrophysiology and arrhythmia research into clear, clinically meaningful insights. Each episode goes beyond headlines and abstracts to uncover what new studies actually mean for patient care, decision-making, and the future of electrophysiology. What EP Edge Journal Watch stands for: Evidence-based practice Precision electrophysiology, arrhythmias analysis A forward-thinking, edge-driven approach to how we interpret and apply data in real-world clinical settings. Whether you’re an electrophysiologist, cardiologist, researcher, trainee, or allied health professional, EP Edge Journal Watch brings you the signal not the noise. Expect sharp summaries, thoughtful commentary, and practical takeaways designed for the busy clinician who wants to stay ahead of the curve","last_synced_at":"2026-09-14T18:19:31.787966+00:00","page_url":"https://stenobird.com/podcast/ep-edge-journal-watch-7561379"},"episode":{"title":"EP Edge Journal Watch Special Edition: VOLT IDE One-Year Results in Context: ADVENT, ADVANTAGE-AF, AdmIRE, SPHERE-Per-AF & U.S. PFA Pivotal Trials","slug":"ep-edge-journal-watch-special-edition-volt-ide-one-year-results-in-context-advent-advantage-af-admire-sphere-per-af-u-s-pfa-pivotal-trials","published_at":"2026-02-06T19:19:46+00:00","page_url":"https://stenobird.com/podcast/ep-edge-journal-watch-7561379/ep-edge-journal-watch-special-edition-volt-ide-one-year-results-in-context-advent-advantage-af-admire-sphere-per-af-u-s-pfa-pivotal-trials","show_page_url":"https://stenobird.com/podcast/ep-edge-journal-watch-7561379","url":"https://share.transistor.fm/s/fd4a1bb4","audio_url":"https://media.transistor.fm/fd4a1bb4/0c45f488.mp3","summary":"Pulsed field ablation (PFA) has rapidly reshaped atrial fibrillation ablation, but true clinical validation depends on durable one-year outcomes, not early feasibility or acute safety alone . In this EP Edge Journal Watch Special Edition , Dr. Niraj Sharma delivers a comprehensive, system-level analysis of the Abbott VOLT IDE one-year data , now completing the 12-month efficacy and safety landscape across major U.S. PFA platforms. This episode critically reviews and contextualizes results from the VOLT IDE trial alongside other pivotal and near-pivotal studies, including ADVENT , ADVANTAGE-AF , AdmIRE , SPHERE-9 first-in-human , and SPHERE-Per-AF . The discussion spans paroxysmal, persistent, and advanced AF populations , with attention to how ablation strategy (PVI-only vs adjunctive lesions), patient risk profile, and post-ablation monitoring intensity influence reported outcomes. Key themes include one-year efficacy versus composite effectiveness , freedom from atrial arrhythmias, repeat procedures, and major safety endpoints such as stroke, tamponade, and esophageal injury. Rather than ranking technologies, this episode emphasizes methodology, trial design, and clinical context , explaining why efficacy signals differ across studies and how these data should be interpreted in everyday electrophysiology practice. For additional references, detailed tables, graphics, and deeper comparative analysis , visit the LinkedIn EP Edge newsletter and Substack at ephedge.substack.com . If you have suggestions or concerns, you can reach Dr. Sharma at ephedgecast@gmail.com","meta_description":"Pulsed field ablation (PFA) has rapidly reshaped atrial fibrillation ablation, but true clinical validation depends on durable one-year outcomes, not earl…","key_points":[],"chapters":[],"topics":[],"duration_seconds":566,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/ep-edge-journal-watch-7561379/episodes/ep-edge-journal-watch-special-edition-volt-ide-one-year-results-in-context-advent-advantage-af-admire-sphere-per-af-u-s-pfa-pivotal-trials/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/ep-edge-journal-watch-7561379/ep-edge-journal-watch-special-edition-volt-ide-one-year-results-in-context-advent-advantage-af-admire-sphere-per-af-u-s-pfa-pivotal-trials.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}}